To help patients adhere to insulin therapy,Becton,Dickinson and Company (BD),a medical technology company,launched BD Glide 6mm Needle in the city on Tuesday. This is BDs smallest insulin syringe needle in India.
The needle,which is designed to improve comfort and is 25 per cent shorter than the contemporary needles available in the market,is believed to be preferred by 80 per cent of patients.
Clinical studies demonstrate that shorter needles like the BD Glide 6mm Needle can effectively deliver insulin to subcutaneous tissue (the layer of fat below the skin) the recommended site for insulin injections while reducing the risk of injecting into muscle (which can increase the risk of hypoglycemia).
Speaking on the occasion,Dr Unnikrishnan AG,CEO and Chief Endocrinologist,Chellaram Diabetes Institute,said,The fear of injections can be addressed with the use of shorter syringe needles. It is important to have a needle that provides consistent,reliable,subcutaneous delivery of insulin to both adults and children. A smaller needle delivers an insulin dose more precisely to the subcutaneous tissue. Moreover,shorter needles provide a less daunting experience to the patients who worry about the pain of insulin injections.
Earlier this year,The Forum for Injection Techniques India (FIT India) recommended that there is no medical reason to recommend needles longer than 6 mm for appropriate insulin delivery to patients. This is due to the fact that longer needles (8mm) have a higher probability (15 per cent) of causing an intramuscular injection compared to shorter needles (6mm reduces probability to 6 per cent) which can increase the risk of hypoglycemia,a potentially life-threatening situation.